NASDAQ:GTHX G1 Therapeutics - GTHX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.84 +0.41 (+5.52%) (As of 01/31/2023 10:57 AM ET) Add Compare Share Share Today's Range$7.45▼$7.8550-Day Range$5.13▼$6.8552-Week Range$3.84▼$17.49Volume477,609 shsAverage Volume959,445 shsMarket Capitalization$336.41 millionP/E RatioN/ADividend YieldN/APrice Target$31.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability G1 Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside263.4% Upside$27.00 Price TargetShort InterestBearish7.20% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.58Based on 5 Articles This WeekInsider TradingSelling Shares$204,976 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.46) to ($2.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.51 out of 5 starsMedical Sector164th out of 1,055 stocksPharmaceutical Preparations Industry73rd out of 518 stocks 4.4 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $27.00, G1 Therapeutics has a forecasted upside of 263.4% from its current price of $7.43.Amount of Analyst CoverageG1 Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.20% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in G1 Therapeutics has recently increased by 20.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 3.1 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for G1 Therapeutics this week, compared to 1 article on an average week.Search Interest30 people have searched for GTHX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows4 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $204,976.00 in company stock.Percentage Held by InsidersOnly 8.09% of the stock of G1 Therapeutics is held by insiders.Percentage Held by Institutions53.13% of the stock of G1 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($3.46) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 2.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About G1 Therapeutics (NASDAQ:GTHX) StockG1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GTHX Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJanuary 30, 2023 | americanbankingnews.comG1 Therapeutics (NASDAQ:GTHX) Upgraded at JPMorgan Chase & Co.January 31, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.January 11, 2023 | finance.yahoo.comG1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology ConferenceJanuary 4, 2023 | msn.comG1 Therapeutics posts early mid-stage results for bladder cancer therapyJanuary 4, 2023 | finance.yahoo.comG1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023January 3, 2023 | finance.yahoo.comG1 Therapeutics to Participate in the 41st Annual J.P. Morgan ConferenceDecember 8, 2022 | seekingalpha.comG1 Therapeutics drug shows promise in initial data from phase 2 breast cancer trialJanuary 31, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.December 7, 2022 | finance.yahoo.comInitial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor MicroenvironmentNovember 28, 2022 | bizjournals.comG1 Therapeutics raises $50M to support commercial, clinical plansNovember 28, 2022 | finance.yahoo.comG1 Therapeutics raises $50M to help lift sales for cancer drugNovember 23, 2022 | finance.yahoo.comG1 Therapeutics to Participate in the Virtual Evercore ISI HealthCONx ConferenceNovember 22, 2022 | finance.yahoo.comG1 Therapeutics Announces Closing of Offering of Common StockNovember 18, 2022 | marketwatch.comG1 Therapeutics Shares Slide Premarket on Public Offering >GTHXNovember 18, 2022 | finance.yahoo.comG1 Therapeutics Announces Proposed Public Offering of Common StockNovember 18, 2022 | finance.yahoo.comG1 Therapeutics Announces Pricing of Offering of Common StockNovember 3, 2022 | finance.yahoo.comNewsflash: G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Revenue ForecastsNovember 2, 2022 | technews.tmcnet.comInitial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)November 2, 2022 | seekingalpha.comG1 Therapeutics rises as trilaciclib potentially reduces adverse events linked with TrodelvyNovember 2, 2022 | finance.yahoo.comG1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer DrugOctober 28, 2022 | finance.yahoo.comIs G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?October 21, 2022 | finance.yahoo.comG1 Therapeutics (NASDAQ:GTHX investor three-year losses grow to 52% as the stock sheds US$50m this past weekOctober 19, 2022 | finance.yahoo.comG1 Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 2, 2022October 12, 2022 | finance.yahoo.comIs G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?October 10, 2022 | finance.yahoo.comG1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)September 14, 2022 | nasdaq.comIs G1 Therapeutics (NASDAQ:GTHX) Using Debt Sensibly?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GTHX Company Calendar Last Earnings11/02/2022Today1/31/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees148Year FoundedN/APrice Target and Rating Average Stock Price Forecast$27.00 High Stock Price Forecast$35.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+298.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-148,350,000.00 Net Margins-328.58% Pretax Margin-325.45% Return on Equity-172.97% Return on Assets-74.56% Debt Debt-to-Equity Ratio1.67 Current Ratio4.24 Quick Ratio3.86 Sales & Book Value Annual Sales$31.48 million Price / Sales10.69 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book2.32Miscellaneous Outstanding Shares42,910,000Free Float39,440,000Market Cap$336.41 million OptionableOptionable Beta1.64 Key ExecutivesMr. John E. Bailey Jr. (Age 58)CEO, Pres & Director Comp: $1.04MMs. Jennifer K. Moses CPA (Age 48)Chief Financial Officer Comp: $606.27kDr. Mark A. Velleca M.D. (Age 59)Ph.D., Sr. Advisor & Director Comp: $242.69kDr. Rajesh K. Malik Ch.B. (Age 64)M.B., M.D., Chief Medical Officer and Sr. VP of R&D Comp: $596.37kMr. Mark Avagliano (Age 47)Chief Bus. Officer Comp: $606.05kMr. Andrew Perry (Age 50)Chief Commercial Officer Comp: $568.6kMr. Terry L. Murdock (Age 63)Chief Operating Officer Mr. Alexander D. Smith M.S.VP of Technical OperationsDr. Jay C. Strum Ph.D. (Age 59)Chief Scientific Officer Mr. William C. Roberts (Age 54)VP of Investor Relations & Corp. Communications More ExecutivesKey CompetitorsRani TherapeuticsNASDAQ:RANISavaraNASDAQ:SVRABiotech AcquisitionNASDAQ:BIOTLianBioNASDAQ:LIANActinium PharmaceuticalsNYSE:ATNMView All CompetitorsInsiders & InstitutionsTerry L MurdockSold 729 sharesTotal: $3,943.89 ($5.41/share)Jennifer K MosesSold 1,639 sharesTotal: $9,145.62 ($5.58/share)Andrew PerrySold 820 sharesTotal: $4,575.60 ($5.58/share)John E (Jack) Jr. BaileySold 32,019 sharesTotal: $187,311.15 ($5.85/share)Bank of New York Mellon CorpBought 3,872 shares on 12/8/2022Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions GTHX Stock - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price forecast for 2023? 6 Wall Street research analysts have issued 12-month price targets for G1 Therapeutics' shares. Their GTHX share price forecasts range from $10.00 to $35.00. On average, they predict the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 263.4% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2023? G1 Therapeutics' stock was trading at $5.43 at the beginning of 2023. Since then, GTHX stock has increased by 36.8% and is now trading at $7.43. View the best growth stocks for 2023 here. Are investors shorting G1 Therapeutics? G1 Therapeutics saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 3,090,000 shares, an increase of 20.2% from the December 31st total of 2,570,000 shares. Based on an average daily volume of 1,160,000 shares, the short-interest ratio is currently 2.7 days. View G1 Therapeutics' Short Interest. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) posted its quarterly earnings results on Wednesday, November, 2nd. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.05. The firm earned $23.58 million during the quarter, compared to analysts' expectations of $22.64 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 172.97% and a negative net margin of 328.58%. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? (GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. What is G1 Therapeutics' stock symbol? G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX." Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew Perry, Glenn P Muir, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is G1 Therapeutics' stock price today? One share of GTHX stock can currently be purchased for approximately $7.43. How much money does G1 Therapeutics make? G1 Therapeutics (NASDAQ:GTHX) has a market capitalization of $318.84 million and generates $46.85 million in revenue each year. The company earns $-148,350,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. How many employees does G1 Therapeutics have? The company employs 148 workers across the globe. How can I contact G1 Therapeutics? G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The official website for the company is www.g1therapeutics.com. The company can be reached via phone at (919) 213-9835, via email at jmacdonald@g1therapeutics.com, or via fax at 919-741-5830. This page (NASDAQ:GTHX) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.